| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
DexCom, Inc.$74.96
+1.93 (+2.64%)
C 42Pipeline Score MedTech · Commercial
Market Cap
27.82 B
EPS
2.39
P/E Ratio
30.84 $
Value Trade
294.33 M
SEC Financials
Q1 2026Dilution Risk
Revenue
1.19 B
R&D Expenses
145.30 M
Operating CF
525.60 M
Total Assets
6.63 B
Total Liabilities
3.68 B
Equity
2.96 B
D/E Ratio
12,345
20.35 %
Week
14.15 %
1 Month
-0.35 %
3 Month
23.25 %
6 Month
-16.31 %
5 Year
2,287.42 %
All Time
Cash Data
Cash Position
2.42 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
Apr 30, 2026
Overview
Volume
3.86 M
52 Week Range
54.11 - 89.98
% held by Insiders
1.76 %
% held by Institutions
98.3 %
Enterprise Value
26.79 B
Total Shares
385.95 M
Short %
4.71 %
Float Shares
384.41 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for DexCom, Inc.
69Total events
2Upcoming
4Tier-1 (high impact)
2018 – 2026Coverage
Upcoming catalysts 2
Event history 67
Jun 6, 2026
▲Full ResultsClinical Data
Dexcom CONNECT Study results demonstrating CGM benefits for people with Type 2 diabetes not using insulin
Type 2 Diabetessource ↗
May 18, 2026
Apr 2026
▲Oral PresentationPresentation
Showcased clinical evidence at ATTD 2026 including one-year registry data for Dexcom G7 in type 2 diabetes not on insulin
type 2 diabetessource ↗
Q1 2026
▲Product LaunchPost-Market
Expanded launch of Dexcom G7 15 Day CGM across all channels in the United States
diabetessource ↗
Mar 2, 2026
◆Oral PresentationPresentation
Dexcom management presentation at 47th Annual Raymond James Institutional Investors Conference
Feb 4, 2026
▲Product LaunchSteloPost-Market
Enhanced Smart Meal Logging and Daily Insights features launch nationwide
glucose managementsource ↗
Drug Pipeline Intelligence
C42
Pipeline Score $519M
Pipeline ValueValuation Signal
2
Drugs Scored0.0x
rNPV / MCap Top 61%
Mid Cap (rank 356 of 911)
Percentile RankDexCom, Inc. carries a moderate pipeline score (42/100), with $610M risk-adjusted pipeline value, led by Sotagliflozin in Diabetic Nephropathies (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sotagliflozin Small molecule | Diabetic Nephropathies | Phase 3 | NCT06217302 | 43% | $538M | RECRUITING | 150 | - | - | May 1, 2029 | MODERATE_RISK | Mar 24, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in DXCM
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
DXCM Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-31 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-31 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-31 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
DXCM▲ +2.6%today
Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
Dexcom, Inc. has announced the release date for its second quarter 2026 financial results, which will occur after market close on July 30, 2026. Following the release, management will conduct a conference call at 4:30 p.m. Eastern Time to discuss the company's performance. The call will also be available via webcast.
Read more →DXCMDexcom Further Advances Vision of Glucose Biosensing for All
Dexcom is making strides in glucose biosensing technology, aiming to enhance accessibility for all users. The company's vision focuses on improving glucose monitoring solutions, although specific advancements or details were not provided in the article. This initiative reflects Dexcom's commitment to innovation in diabetes management.
Read more →DXCM▲ +5.2%on this news
Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
The article mentions the Dexcom CONNECT Study, which highlights the benefits of continuous glucose monitoring (CGM) for individuals with Type 2 diabetes who are not using insulin. However, the content is limited and does not provide detailed findings or implications from the study.
Read more →DXCMDexcom Uncovers Theft of Scrapped Product, Notifies Potentially Impacted Users
Dexcom has reported a theft involving a scrapped product, which may have implications for users. The company is actively notifying those who might be affected by this incident. This situation raises concerns about product security and the potential risks to user safety.
Read more →DXCM▲ +5.6%on this news· ran to +17% by day 3
Redefining CGM for People With Type 2 Diabetes: Dexcom Announces Dexcom Flex in Germany
Dexcom has announced the launch of Dexcom Flex, a continuous glucose monitoring (CGM) system aimed at individuals with type 2 diabetes in Germany. This new product is expected to enhance diabetes management for patients. Further details about the features and benefits of Dexcom Flex were not provided in the announcement.
Read more →DXCMDexcom Announces Governance Enhancements Ahead of 2026 Investor Day
Dexcom has announced governance enhancements as it prepares for its 2026 Investor Day. The details of these enhancements have not been disclosed in the article, but they indicate a proactive approach to corporate governance ahead of the event.
Read more →DXCMDexcom to Host Investor Day on May 14, 2026
Dexcom has announced that it will host an Investor Day on May 14, 2026. This event is expected to provide insights into the company's future strategies and developments. Further details about the agenda and speakers have yet to be disclosed.
Read more →DXCMDexcom Reports First Quarter 2026 Financial Results SAN DIEGO - (BUSINESS WIRE
Dexcom, Inc. reported strong financial results for the first quarter of 2026, highlighting a 15% increase in revenue year-over-year, reaching $1.192 billion. The company achieved significant growth in both U.S. (11%) and international (26%) markets, with notable improvements in gross and operating margins. Furthermore, Dexcom has raised its 2026 guidance for key financial metrics, reflecting ongoing operational improvements. The adoption of the Dexcom G7 continuous glucose monitoring system and enhanced Stelo platform features contribute positively to its growth outlook.
Read more →DXCMDexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time
Dexcom has announced the schedule for its first quarter 2026 earnings release and conference call. The event is set for April 30, 2026, at 4:30 p.m. Eastern Time. This announcement provides stakeholders with a timeline for financial updates.
Read more →DXCMDexcom Announces Upcoming March 2026 Conference Presentation
Dexcom, Inc. has announced that its management will present at the 47th Annual Raymond James Institutional Investors Conference on March 2, 2026. The presentation will begin at approximately 1:05 PM EST and will be available via live webcast. This event underscores Dexcom's ongoing commitment to investor relations and transparency.
Read more →DXCMDexcom Appoints Rick Osterloh to Board of Directors SAN DIEGO - (BUSINESS WIRE
Dexcom, Inc. has announced the appointment of Rick Osterloh to its Board of Directors, effective February 26, 2026. Osterloh, a prominent technology leader at Google, brings over 20 years of experience in consumer products and innovation. His appointment is seen as a strategic move to bolster Dexcom's mission in improving metabolic health through advanced biosensing technologies. The company aims to leverage his expertise in product development and long-term strategic planning.
Read more →DXCMDexcom Reports Fourth Quarter and Fiscal Year 2025 Financial Results SAN DIEGO - (BUSINESS WIRE
Dexcom reported strong financial results for the fourth quarter and fiscal year 2025, highlighting a 13% increase in revenue year-over-year, totaling $1.260 billion for Q4. Notably, the company's operating income rose significantly, reflecting improved profit margins. Strategic initiatives included the launch of the Dexcom G7 CGM system and FDA clearance for the Dexcom Smart Basal. Dexcom's outlook for 2026 includes anticipated revenue growth of 11-13%, positioning the company well in the diabetes management market.
Read more →DXCMStelo Adds Enhanced Smart Meal Logging Features as Dexcom Continues to Transform Personal Glucose Management
Dexcom is set to enhance its Stelo app with advanced AI features aimed at improving personal glucose management. The update includes a comprehensive nutrition database for meal logging and a redesigned Daily Insights feature that offers personalized recommendations. Users have reported positive changes in their dietary habits and overall health management since using Stelo. The new features will be available on iOS and Android in the coming weeks.
Read more →DXCMDexcom Schedules Fourth Quarter and Fiscal Year 2025 Earnings Release and Conference Call for February 12, 2026 at 4:30 p.m. Eastern Time.
Dexcom, Inc. has announced its plans to release its fourth quarter and fiscal year 2025 financial results on February 12, 2026. A conference call will follow at 4:30 p.m. Eastern Time to discuss the results. The call will also be available via webcast on the company's investor relations website.
Read more →DXCMDexcom Enters Next Era of Continued Innovation with Jake Leach as President and Chief Executive Officer Mr. Leach begins his inaugural year as CEO with speaking engagements at CES 2026 and the 44 th annual J.P. Morgan He
Dexcom has appointed Jake Leach as the new President and CEO, signifying a new phase of innovation for the company. He will be speaking at prominent events like CES 2026 and the J.P. Morgan Healthcare Conference to present his vision for Dexcom's future. The company plans to launch an enhanced Stelo app and has increased the availability of its Dexcom G7 15 Day CGM System. Dexcom remains dedicated to advancing user experiences and expanding access to glucose monitoring technology for those with diabetes.
Read more →DXCMListening to Healthcare Professionals: Dexcom Launches New Education Offering, Dexcom Academy
Dexcom has launched Dexcom Academy, a personalized learning platform designed for healthcare professionals to enhance their understanding of continuous glucose monitoring (CGM). The platform, available in several EMEA countries, offers flexible, bite-sized educational modules tailored to the needs of HCPs. It aims to improve confidence in CGM use and support diabetes care without adding to clinical burdens.
Read more →DXCMDexcom Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Guidance SAN DIEGO - (BUSINESS WIRE
Dexcom, Inc. reported strong financial results for the third quarter of 2025, with revenue increasing by 22% year-over-year to $1.209 billion. The company also raised its fiscal year 2025 revenue guidance, citing significant growth opportunities ahead. Notable achievements included launching an AI-powered meal logging feature and expanding access to the Dexcom G7 product in Canada. The company's strategic moves aim to capitalize on evolving market demands amid financial growth.
Read more →DXCMDexcom Appoints Euan Ashley to Board of Directors SAN DIEGO - (BUSINESS WIRE
Dexcom, a leader in glucose biosensing, has appointed Dr. Euan Ashley to its Board of Directors, effective October 24, 2025. Dr. Ashley is a prominent figure in healthcare innovation, currently serving as Chair of the Department of Medicine at Stanford University. His expertise spans precision medicine, digital health, and entrepreneurship, which is expected to enhance Dexcom's strategic direction. The appointment is part of Dexcom's ongoing commitment to improving metabolic health across populations.
Read more →DXCMDexcom Reports Second Quarter 2025 Financial Results, Updates Full Year 2025 Guidance and Announces CEO Succession Plan SAN DIEGO - (BUSINESS WIRE
Dexcom, Inc. reported significant growth in its financial results for the second quarter of 2025, with a 15% year-over-year increase in revenue to $1.157 billion. The company also received FDA clearance for its new Dexcom G7 15 Day CGM System and introduced an AI-based Smart Food Logging feature. Additionally, Dexcom announced a CEO succession plan, promoting Jake Leach to the role effective January 1, 2026, while current CEO Kevin Sayer remains involved as executive chairman. The updated guidance for full-year revenue indicates ongoing confidence in the company's growth trajectory.
Read more →DXCMDexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO SAN DIEGO--(BUSINESS WIRE)
Dexcom has announced the promotion of Jake Leach to the role of president while retaining his position as chief operating officer. With over 21 years of experience at the company, Leach has been integral to the development of Dexcom's biosensing platforms. His new responsibilities will include overseeing corporate development and strategy efforts, building on the company's commitment to innovation in metabolic health.
Read more →DXCMDexcom Reports First Quarter 2025 Financial Results and Announces $750 Million Share Repurchase Program SAN DIEGO - (BUSINESS WIRE
Dexcom, Inc. reported its first quarter 2025 financial results with revenues growing 12% year-over-year to $1.036 billion. The company also announced a $750 million share repurchase program. Strategic highlights include an FDA clearance for the Dexcom G7 15 Day System and expanded coverage in the U.S. healthcare market. Despite a decline in non-GAAP operating income and lower gross profit margins, Dexcom remains optimistic about its future prospects and revenue guidance.
Read more →DXCM▼ -9.1%on this news
Dexcom Appoints Ren e Gal to Board of Directors SAN DIEGO - (BUSINESS WIRE
DexCom, Inc. has appointed Ren e Gal to its Board of Directors effective March 6, 2025. Ms. Gal, currently President and COO of Jazz Pharmaceuticals, brings extensive operational and financial expertise in the life sciences sector. Her leadership experience at high-growth companies and track record in global business operations are expected to enhance Dexcom's strategic direction. The appointment comes at a pivotal time for Dexcom as it seeks to expand its impact on metabolic health globally.
Read more →DXCMDexcom Reports Fourth Quarter and Fiscal Year 2024 Financial Results SAN DIEGO - (BUSINESS WIRE
DexCom, Inc. reported its financial results for the fourth quarter and fiscal year 2024, showing an 8% revenue growth year-over-year to $1.114 billion. The company noted decreased operating income margins, with GAAP operating income at 17% of revenue compared to 21% in Q4 2023. Significant international market expansion was highlighted, including a 17% increase in international revenue. DexCom also secured reimbursement for its ONE+ product in France, further enhancing its market access.
Read more →DXCMDealer name and address ] May [__], 2023 To: DexCom, Inc. 6340 Sequence Drive San Diego, CA 92121 Attention: Leslie Ludtke, Treasurer Telephone No.: Email address: Re: [Base][Additional] Call Option Transaction The purpo
DexCom, Inc. has confirmed a call option transaction with a dealer, involving their Convertible Senior Notes due in 2028. This confirmation serves to establish the binding agreement between the two parties, specifying the details of the call option transaction. The agreement incorporates terms from the ISDA Master Agreement and outlines key transaction details including trade and expiration dates, option type, and pricing structures.
Read more →DXCMDEXCOM PRICES UPSIZED OFFERING OF $1.1 BILLION OF 0.375% CONVERTIBLE SENIOR NOTES DUE 2028 SAN DIEGO, CA. - (BUSINESS WIRE
Dexcom, Inc. has announced the successful pricing of an upsized offering of $1.1 billion in 0.375% Convertible Senior Notes due 2028. This private placement is expected to close on May 5, 2023, and will enhance Dexcom's financial flexibility for future investments and stock repurchases. The offering also includes an option for purchasers to buy an additional $150 million in notes. Proceeds from the offering will be allocated for various corporate needs, including share repurchases and capital expenditures.
Read more →DXCMDEXCOM ANNOUNCES PROPOSED OFFERING OF $1.0 BILLION OF CONVERTIBLE SENIOR NOTES SAN DIEGO, CA. (BUSINESS WIRE
DexCom, Inc. announced its intention to offer $1.0 billion in convertible senior notes due 2028, aimed at qualified institutional buyers. The offering includes a potential additional $150 million of notes within a specified period. Proceeds from the offering are earmarked for various uses, including share repurchases and capital expenditures. However, the successful execution of this offering is contingent upon market conditions and investor appetite.
Read more →DXCMDexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter 2021 and Summary Data from the Dexcom G7 U.S. Pivotal Trial SAN DIEGO, CA - (BUSINESS WIRE
Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter 2021 and Summary Data from the Dexcom G7 U.S. Pivotal Trial SAN DIEGO, CA - (BUSINESS WIRE-January 10, 2022) - DexCom, Inc. (Nasdaq: DXCM), the leader in real-time continuous glucose monitoring ( CGM ), today
Read more →DXCMDexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2020 and Provides Initial 2021 Outlook SAN DIEGO, CA - (BUSINESS WIRE
Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2020 and Provides Initial 2021 Outlook SAN DIEGO, CA - (BUSINESS WIRE-January 11, 2021) - DexCom, Inc. (Nasdaq: DXCM), the leader in continuous glucose monitoring ( CGM ), today reported that i
Read more →DXCMDexcom Announces Retirement of Rick Doubleday and Pre-Announcement of Third Quarter 2020 Revenue SAN DIEGO (BUSINESS WIRE) DexCom, Inc . (NASDAQ:DXCM) today announced that Rick Doubleday, Executive Vice President and Chi
Dexcom Announces Retirement of Rick Doubleday and Pre-Announcement of Third Quarter 2020 Revenue SAN DIEGO (BUSINESS WIRE) DexCom, Inc. (NASDAQ:DXCM) today announced that Rick Doubleday, Executive Vice President and Chief Commercial Officer, will retire at the end of 2020 in o
Read more →DXCMDocument Dexcom Appoints Kyle Malady to Board of Directors SAN DIEGO--(BUSINESS WIRE)
Dexcom Appoints Kyle Malady to Board of Directors SAN DIEGO--(BUSINESS WIRE)-October 13, 2020-- DexCom, Inc. (NASDAQ DXCM), the global leader in real-time continuous glucose monitoring, today announced the appointment of Kyle Malady to its Board of Directors, effective immediate
Read more →DXCMDexcom Appoints Karen Dahut to Board of Directors SAN DIEGO (BUSINESS WIRE)
Dexcom Appoints Karen Dahut to Board of Directors SAN DIEGO (BUSINESS WIRE) August 12, 2020 DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring, today announced the appointment of Karen Dahut to its Board of Directors, effective immediately
Read more →DXCMNOTICE OF FULL REDEMPTION DexCom, Inc.
NOTICE OF FULL REDEMPTION Pursuant to that certain Indenture dated as of May 12, 2017 (the Indenture ) between DexCom, Inc., a Delaware corporation (the Company ), and U.S. Bank National Association, as Trustee (the Trustee ), the Company originally issued $400,000,000 in princ
Read more →DXCMDEXCOM PRICES OFFERING OF UPSIZED $1.05 BILLION OF 0.25% CONVERTIBLE SENIOR NOTES SAN DIEGO, CA. - (BUSINESS WIRE
DEXCOM PRICES OFFERING OF UPSIZED $1.05 BILLION OF 0.25% CONVERTIBLE SENIOR NOTES SAN DIEGO, CA. - (BUSINESS WIRE-May 12, 2020) - DexCom, Inc. (Nasdaq: DXCM) ( DexCom ) announced today the pricing of its offering of $1.05 billion aggregate principal amount of 0.25% Convertible
Read more →DXCMDEXCOM ANNOUNCES PROPOSED OFFERING OF $850.0 MILLION OF CONVERTIBLE SENIOR NOTES SAN DIEGO, CA. - (BUSINESS WIRE
DEXCOM ANNOUNCES PROPOSED OFFERING OF $850.0 MILLION OF CONVERTIBLE SENIOR NOTES SAN DIEGO, CA. - (BUSINESS WIRE-May 11, 2020) - DexCom, Inc. (Nasdaq: DXCM) ( DexCom ) announced today that it intends to offer, subject to market conditions and other factors, $850.0 million aggre
Read more →DXCMDexcom Reports Record Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2019 and Provides Initial 2020 Outlook SAN DIEGO, CA - (BUSINESS WIRE
Dexcom Reports Record Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2019 and Provides Initial 2020 Outlook SAN DIEGO, CA - (BUSINESS WIRE-January 13, 2020) - DexCom, Inc. (Nasdaq: DXCM), the leader in continuous glucose monitoring ( CGM ), today reported
Read more →DXCMDexcom Appoints Bridgette Heller to Board of Directors
Dexcom Appoints Bridgette Heller to Board of Directors SAN DIEGO--(BUSINESS WIRE)-September 17, 2019-- DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring, today announced the appointment of Bridgette Heller to its Board of Directors, effect
Read more →DXCMDexcom Reports Record Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2018 and Provides Initial 2019 Outlook SAN DIEGO, CA - (BUSINESS WIRE
Dexcom Reports Record Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2018 and Provides Initial 2019 Outlook SAN DIEGO, CA - (BUSINESS WIRE-January 7, 2019) DexCom, Inc. (Nasdaq: DXCM), the leader in continuous glucose monitoring ( CGM ), today reported th
Read more →DXCMDEXCOM PRICES OFFERING OF $750.0 MILLION OF 0.75% CONVERTIBLE SENIOR NOTES SAN DIEGO, CA. - (BUSINESS WIRE
DEXCOM PRICES OFFERING OF $750.0 MILLION OF 0.75% CONVERTIBLE SENIOR NOTES SAN DIEGO, CA. - (BUSINESS WIRE-November 28, 2018) - DexCom, Inc. (Nasdaq: DXCM) ( DexCom ) announced today the pricing of its offering of $750.0 million aggregate principal amount of 0.75% Convertible S
Read more →DXCMDealer Header] [JPMorgan Chase Bank, National Association London Branch 25 Bank Street Canary Wharf London E14 5JP England] [Bank of America, N.A. c/o Merrill Lynch, Pierce, Fenner & Smith Incorporated One Bryant Park Ne
[JPMorgan Chase Bank, National [Bank of America, N.A. c/o Merrill Lynch, Pierce, Fenner & Smith Incorporated Telephone: 646-855-0711 Attention: Chief Financial Officer The purpose of this letter agreement (this Confirmation ) is to confirm the terms and conditions of the cal
Read more →DXCMDEXCOM ANNOUNCES PROPOSED OFFERING OF $750 MILLION OF CONVERTIBLE SENIOR NOTES SAN DIEGO, CA. - (BUSINESS WIRE
DEXCOM ANNOUNCES PROPOSED OFFERING OF $750 MILLION OF CONVERTIBLE SENIOR NOTES SAN DIEGO, CA. - (BUSINESS WIRE-November 26, 2018) - DexCom, Inc. (Nasdaq: DXCM) ( DexCom ) announced today that it intends to offer, subject to market conditions and other factors, $750 million aggr
Read more →DXCMDEXCOM, INC. (THE ISSUER ) HAS FILED A REGISTRATION STATEMENT (INCLUDING A PROSPECTUS) WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION (THE SEC ) FOR THE OFFERING TO WHICH THIS COMMUNICATION RELATES. BEFORE YOU
DEXCOM, INC. (THE ISSUER ) HAS FILED A REGISTRATION STATEMENT (INCLUDING A PROSPECTUS) WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION (THE SEC ) FOR THE OFFERING TO WHICH THIS COMMUNICATION RELATES. BEFORE YOU INVEST, YOU SHOULD READ THE PROSPECTUS CONTAINED IN THE RE
Read more →Competitive Position
How DXCM ranks across every disease it competes inCompetitive Position is a premium feature
See how DXCM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial